PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Gut. 2007 June; 56(6): 746–748.
PMCID: PMC1954880

Cardiovascular determinants of survival in cirrhosis

Short abstract

Diastolic response as the strongest determinant of mortality after TIPS

My heart,

Where either I must live or bear no life,

The fountain from which my current runs

Or dries up

William Shakespeare, Othello

Cirrhosis is a fatal condition. Although mild cirrhosis can be associated with prolonged survival, most diseases that induce cirrhosis progress, at variable rates, to end‐stage liver failure. Deaths from hepatic failure, variceal bleeding and infection are common in advanced cirrhosis, and even the rate of sudden unexplained death is increased compared with that in a normal population.1 Moreover, patients with cirrhosis are well known to be fragile, and do poorly after invasive or stressful procedures. It is logical and intuitive to assume that the sickest patients—that is, those with the most advanced degree of liver failure—will have the poorest outcome after challenges. Indeed, this is what virtually all studies on risk factors for morbidity and mortality in cirrhosis show.2 Mortality following a variceal bleed is strongly correlated with the degree of liver dysfunction as estimated by the Child–Pugh score, with death rates of 10–15% in class A, 20–30% in class B and 40–50% in class C patients. Similar correlations have been shown using the Model End‐stage Liver Disease (MELD) score to estimate liver function. Cardiovascular surgery carries greater risks in those with advanced liver dysfunction than in those with mild liver dysfunction.3

In all these studies, the assumption was made that deaths were wholly or predominantly due to liver failure. Indeed, a recent exhaustive systematic review of the entire world literature to 2006, analysing 118 studies that examined risk factors predictive of death in patients with cirrhosis, found that liver function, as assessed by the Child–Pugh score or the MELD score, consistently emerged as the best predictor of mortality in the majority of studies.2 However, virtually no studies have examined cardiac contractile function as a predictor of mortality, except by indirect measures such as cardiac output or diastolic arterial pressure.

Transjugular intrahepatic portosystemic shunt (TIPS) insertion has become increasingly popular over the past decade as a non‐operative approach to treat resistant ascites or intractable variceal bleeding in patients with cirrhosis. TIPS insertion poses a significant cardiovascular challenge, as it suddenly shifts a significant amount of splanchnic venous blood to the systemic veins—that is, increases preload. Not surprisingly, this procedure, almost invariably performed in patients with advanced liver dysfunction, is also associated with high mortality. A meta‐analysis of 330 patients in five randomised trials of TIPS in refractory ascites revealed a 1‐year and 2‐year mortality of 38% and 50%, respectively.4 Yoon et al5 reported that after TIPS, 31% of patients died within 30 days of stent insertion, and 59% died during a 35‐month follow‐up period. Multivariate analysis showed that only hyperbilirubinaemia and increased serum creatinine were independent predictors of death.5 However, cardiac function was not examined in that study. Another study, using multivariate analyses showed that creatinine level >1.7 mg/dl and uncontrolled variceal bleeding were independently associated with 30‐day mortality after TIPS.6 This study also did not consider cardiac function.

All deaths, of course, ultimately involve some form of cardiac arrest as an agonal event. Even deaths due to liver failure from sepsis, multi‐organ failure, adult respiratory distress syndrome, and so on, eventually result in cardiac arrest. Given this line of reasoning, it is perhaps understandable that the agonal event would not merit consideration as the primary causative factor in death. This type of thinking may explain the previously unnoticed ‘hole' in the hepatology literature—that is, ignoring the possible role of the heart.

In view of this background, the pioneering nature of the study by Cazzaniga et al7 (see page 867) can be appreciated. They prospectively examined the prognostic utility of not just the usual indices of liver function such as MELD score, but also cardiac function parameters such as the diastolic E/A ratio in patients undergoing a TIPS procedure.7 Only early diastolic (E)/late‐diastolic filling velocity (A) <1 at day 28 post‐TIPS and baseline MELD score were univariate predictors of 1‐year mortality. On multivariate analysis, only the day 28 E/A was a significant predictor of death. The E/A ratio is the echocardiographic measurement of the E (early) wave velocity of blood filling the ventricle during the initial part of diastole divided by the velocity of late diastolic filling wave (called A wave as the “atrial kick” predominates during this stage). As the failing or hypertrophic ventricle loses elasticity and compliance, the normally dominant “sucking” inflow during early diastole diminishes, and the late‐diastolic atrial kick becomes increasingly important for filling. An E/A <1 is generally considered abnormal. The E/A is well accepted as a simple, reproducible measure of diastolic compliance and is often the first ventricular contractile abnormality in cardiac patients with congestive heart failure.8

The normal heart should easily accommodate the mild‐to‐moderate increase in preload induced by a TIPS insertion. This inability to accommodate an increased preload is yet another evidence of the existence of a syndrome now emerging from years of obscurity, cirrhotic cardiomyopathy.9,10,11 When first described almost two decades ago, cirrhotic cardiomyopathy was a scientific “homeless waif”. Many doubted its existence, and it seemed to have little or no clinical relevance as severe congestive heart failure is rare in cirrhosis. Over the past few years, that situation has changed dramatically. The explanation for the rarity of overt heart failure is the marked peripheral vasodilatation, which reduces ventricular afterload and thus “auto‐treats” the patient. Recently, compelling evidence of a significant role of inadequate cardiac contractile responsiveness in the pathogenesis of hepatorenal syndrome has been reported in two studies by Ruiz‐del‐Arbol et al12,13. Firstly, they showed that insufficient cardiac response to infection in patients with spontaneous bacterial peritonitis contributed to the development of hepatorenal syndrome after infection resolution.12 Secondly, among 66 patients with tense ascites, a subgroup of 27, who went on to develop hepatorenal syndrome, could be distinguished by a lower baseline cardiac output than the group that did not.13 As underscored in our accompanying editorial,14 these data strongly suggest that an insufficient cardiac response to infection stress or other stimulus in the patient with advanced cirrhosis reduces arterial pressure and renal perfusion and thus contributes to the pathogenesis of hepatorenal syndrome.

Cirrhotic cardiomyopathy may also help determine outcomes after liver transplantation. Before the syndrome was widely recognised, transplant physicians were puzzled by the apparently inexplicable appearance of sometimes severe cardiac dysfunction in the postoperative period, often in patients with no previous history or risk factors for heart disease. Moreover, despite careful cardiac workup and exclusion of those with overt heart disease, 12–56% of patients develop clinically‐ or radiographically‐evident pulmonary oedema during the postoperative period.15 It is now becoming increasingly clear that these problems reflect the presence of underlying cirrhotic cardiomyopathy.15,16

An expert working group is developing a consensus definition of cirrhotic cardiomyopathy, with the results expected in 2007. For now, it can be generally defined as attenuated systolic and diastolic ventricular contractile responses to stress stimuli in the absence of a primary heart disease in the patient with cirrhosis. Other associated features can include electrophysiological repolarisation changes including prolonged electrocardiographic QT interval and enlargement or hypertrophy of cardiac chambers.

Several studies have reported an abnormal cardiac response to TIPS insertion, ranging from mild contractile or diastolic dysfunction17,18 to precipitation of overt heart failure. Such heart failure has been reported sporadically as individual case reports,15 as well as in randomised trials. For example, in a randomised trial comparing TIPS with repeated large‐volume paracentesis to treat resistant ascites, heart failure was reported in 12% of the TIPS group,19 versus none in the paracentesis group. However, heart failure was not reported in four other randomised trials of TIPS in refractory ascites. Moreover, many patients actually improve some indices of cardiac function after TIPS. Like most populations afflicted with end‐stage liver failure, the patients who receive TIPS are heterogeneous. Indeed, this study suggests that TIPS insertion serves as a significant cardiac challenge that may distinguish those with cirrhotic cardiomyopathy from those who have relatively intact cardiac function. The overall effect of TIPS was beneficial to cardiac function, as the mean baseline E/A of 0.97 increased to a mean of 1.19 4 weeks later, and the number of patients with E/A <1 decreased from 18 to 10. However, after 1 year of follow‐up, the only deaths were observed in the 10 patients with E/A <1 (6 died). In other words, the presence of cirrhotic cardiomyopathy unmasked by the TIPS challenge identified a subgroup with a very poor medium‐term prognosis.

A preliminary report generally supports the findings of the Italian study. A retrospective combined analysis of 101 consecutive patients undergoing TIPS from 1997–2005 in the authors' centre and in Toronto found that the baseline E/A was the only factor on multivariate analysis predictive of mortality after TIPS.20 As that study was retrospective, the 4‐week post‐TIPS E/A data was not available. However, these results again suggest the prognostic significance of diastolic dysfunction.

The central question posed by the study of Cazzaniga et al7 is which organ failure played a greater role in post‐TIPS mortality: the liver or the heart? This observational study cannot definitively answer this question, and the authors are therefore appropriately cautious in their interpretation and extrapolation of the results. Trying to answer this question is enormously complicated by the positive correlation between degree of liver failure and diastolic dysfunction. Several studies have demonstrated that the extent of cirrhotic cardiomyopathy worsens as liver disease progresses.11 Thus, the degree of systolic contractile dysfunction,21 diastolic changes22,23 and electrophysiological abnormalities such as QT prolongation24 are greater in those with more advanced liver failure. The correlation between degree of liver failure and cardiac response was also observed in this study, with a positive interaction between MELD score and the E/A ratio at day 28. However, the most obvious conclusion of the multivariate analysis is that the diastolic response to TIPS is the strongest determinant of post‐procedure mortality.

No deaths were due to overt cardiac failure in the study. Does this cast doubt on the notion that cirrhotic cardiomyopathy played a central role in mortality? We believe not. First, overt severe heart failure is rare in cirrhosis for the reasons mentioned previously. Second, the most common cause of death was hepatorenal syndrome, and all such cases were observed in the group with post‐TIPS diastolic dysfunction. The contributory role of cardiac dysfunction in pathogenesis of hepatorenal syndrome has been noted above.

These intriguing results need to be confirmed in a larger cohort of patients. Another question that the study raises is how to predict poor outcomes from baseline factors rather than variables occurring after TIPS insertion. Two‐dimensional echocardiography is non‐invasive and inexpensive; we believe that that all patients undergoing TIPS should have this examination 4 weeks later, and those who have diastolic dysfunction must be carefully followed. Finally, this study underscores the need to examine cardiac function as a prognostic factor not just in TIPS but also in patients with cirrhosis undergoing cardiovascular stresses such as haemorrhage, shock, infection and surgery, particularly liver transplantation.

Footnotes

Competing interests: None.

References

1. Penttila A. Sudden and unexpected natural deaths of adult males. An analysis of 799 forensic autopsies in 1976. Forensic Sci Int 1980. 16249–259.259 [PubMed]
2. D'Amico G, Garcia‐Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006. 44217–231.231 [PubMed]
3. Suman A, Barnes D S, Zein N N. et al Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child‐Pugh and MELD scores. Clin Gastroenterol Hepatol 2004. 2719–723.723 [PubMed]
4. Deltenre P, Mathurin S, Dharancy R. et al Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta‐analysis. Liver Int . 2005;25349–356.356
5. Yoon C J, Chung J W, Park J H. Transjugular intrahepatic portosystemic shunt for acute variceal bleeding in patients with viral liver cirrhosis: predictors of early mortality. Am J Roentgenol 2005. 185885–889.889 [PubMed]
6. Russo M W, Jacques P F, Mauro M. et al Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl 2002. 8271–277.277 [PubMed]
7. Cazzaniga M, Salerno F, Pagnozzi G. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 2007. 56867–873.873
8. Oh J K, Hatle L, Tajik A J. et al Diastolic heart failure can be diagnosed by comprehensive two‐dimensional and Doppler echocardiography. J Am Coll Cardiol 2006. 47500–506.506 [PubMed]
9. Ma Z, Lee S S. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996. 24451–459.459 [PubMed]
10. Moller S, Henriksen J H. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002. 879–15.15 [PMC free article] [PubMed]
11. Liu H, Gaskari S A, Lee S S. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006. 12837–842.842 [PubMed]
12. Ruiz‐del‐Arbol L, Urman J, Fernandez J. et al Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003. 381210–1218.1218 [PubMed]
13. Ruiz‐del‐arbol L, Monescillo A, Arocens C. et al Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005. 42439–447.447 [PubMed]
14. Lee S S. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology 2003. 381089–1091.1091 [PubMed]
15. Gaskari S A, Honar H, Lee S S. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006. 3329–337.337 [PubMed]
16. Myers R P, Lee S S. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000. 6S44–S52.S52 [PubMed]
17. Huonker M, Schumacher Y O, Ochs A. et al Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999. 44743–748.748 [PMC free article] [PubMed]
18. Merli M, Valeriano V, Funaro S. et al Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002. 97142–148.148 [PubMed]
19. Gines P, Uriz J, Calahorra B. et al Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002. 1231839–1847.1847 [PubMed]
20. Rabie R, Cazzaniga M, Salerno F. et al Effect of cirrhotic cardiomyopathy on post‐TIPS outcome of patients treated for complications of portal hypertension. Hepatology 2006. 44(Suppl 1)444A
21. Wong F, Girgrah N, Graba J. et al The cardiac response to exercise in cirrhosis. Gut 2001. 49268–275.275 [PMC free article] [PubMed]
22. Pozzi M, Carugo S, Boari G. et al Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997. 261131–1137.1137 [PubMed]
23. Salerno F, Cazzaniga M, Pagnozzi G. et al Humoral and cardiac effects of TIPS in cirrhotic patients with different “effective” blood volume. Hepatology 2003. 381370–1377.1377 [PubMed]
24. Bernardi M, Calandra S, Colantoni A. et al Q‐T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998. 2728–34.34 [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group